How much revenue does the in vivo CRO market generate?

The market revenue for in vivo CRO is anticipated at USD 6.28 billion in 2027.

How is the in vivo CRO industry size expected to evolve during the forecast period?

In Vivo CRO Market size was over USD 5.9 billion in 2026 and is likely to grow at a 7.6% CAGR between 2027 and 2036, exceeding USD 12.27 billion by 2036.

How is outsourcing in oncology and rare disease research shaping demand for in vivo CRO services?

Increasing outsourcing of oncology and rare disease research is driving demand for in vivo CROs with specialized disease models and technical expertise to conduct pharmacology, efficacy, and toxicology studies, enabling sponsors to progress programs without building internal niche preclinical infrastructure.

Which technological and regulatory shifts are expanding demand for specialized in vivo CRO capabilities in advanced biologics development?

Cell and gene therapy pipelines and rising biologics regulatory complexity are increasing demand for in vivo CROs with specialized models, analytical workflows, and regulatory-aligned study design expertise to support biodistribution, immunogenicity, and safety evaluation for advanced therapies.

Why do rodent based models hold the largest share in the in vivo CRO market?

Rodent based models lead with 77.85% share due to their established role in preclinical efficacy, toxicity, and disease-model studies, enabling standardized, efficient, and widely accepted in vivo research workflows.

Why are non-rodent models gaining momentum in this market?

Non-rodent models are the fastest-growing segment as complex drug programs require broader translational validation in later-stage safety and pharmacology studies beyond standard rodent-based research frameworks.

Why does North America lead the in vivo CRO market?

North America leads with 53.00% share supported by strong preclinical ecosystem, outsourcing of in vivo studies, experienced CROs, and steady pharma-biotech demand for toxicology and pharmacology.

What is driving Asia Pacific growth in the in vivo CRO market?

Asia Pacific is projected at 9.27% CAGR driven by expanding pharma-biotech research, outsourced preclinical studies, scalable CRO capacity, and growing scientific talent base.

What are the prominent companies operating in the in vivo CRO landscape?

Key companies in the in vivo CRO market include IQVIA Inc. (United States), Charles River Laboratories International, Inc. (United States), Laboratory Corporation of America Holdings (United States), Parexel International Corporation (United States), ICON plc (Ireland), Evotec SE (Germany), Crown Bioscience Inc. (United States), Taconic Biosciences, Inc. (United States), Janvier Labs (France), Biocytogen Pharmaceuticals Co., Ltd. (China).